Appointment of Dr. Annalisa Jenkins Non-Executive Chair at Silence Therapeutics

https://www.youtube.com/watch?v=nSXOz1ddSpI&feature=youtu.be

Ali Mortazavi, Chief Executive Officer at Silence Therapeutics plc (LON:SLN) spoke to Proactive Investors about their announcement of as Non-Executive Chair, Dr. Annalisa Jenkins.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Silence Therapeutics plc

    More articles like this

    Silence Therapeutics plc

    Silence Therapeutics analyst presentation 6th March

    Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce its Preliminary Results for the twelve months ended

    Silence Therapeutics plc

    A further European patent for Silence Therapeutics plc

    Silence Therapeutics plc, AIM:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that on 17 January 2018 the European Patent

    Silence Therapeutics plc

    Silence Therapeutics Notice of Interim Results

    Silence Therapeutics plc, LON:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce results for the six